$AGIO: Agios Pharmaceuticals Announces Positive Phase 3 Results for Mitapivat in Thalassemia, 30.4% vs. 12.6%

Jun 3, 2024, 10:34 AM

Agios Pharmaceuticals ($AGIO) has announced that its Phase 3 ENERGIZE-T study of Mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia met its primary endpoint and all key secondary endpoints. The study demonstrated a significant transfusion reduction response, with 30.4% of participants showing improvement compared to 12.6% in the placebo group. This positive outcome, announced on June 3, 2024, marks a potential novel advancement in care for patients with this inherited blood disorder.